Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement Post author:GHIAA Admin Post published:June 29, 2022 Post category: Continue ReadingNIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement Post author:GHIAA Admin Post published:May 31, 2022 Post category: Continue ReadingElkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
CSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement Post author:GHIAA Admin Post published:May 23, 2022 Post category: Continue ReadingCSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement Post author:GHIAA Admin Post published:March 3, 2022 Post category: Continue ReadingBiological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
Merck – MPP, Molnupiravir License Agreement Post author:GHIAA Admin Post published:November 22, 2021 Post category: Continue ReadingMerck – MPP, Molnupiravir License Agreement
University of Liverpool – MPP, Solid Drug Nanoparticle Technology License Agreement Post author:GHIAA Editor Post published:May 21, 2020 Post category: Continue ReadingUniversity of Liverpool – MPP, Solid Drug Nanoparticle Technology License Agreement